The Company received 180-day competitive generic therapy exclusivity from the FDA. The first generic version of FML suspension (fluorometholone ophthalmic suspension) has been made available by Amneal ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced the approval and launch of fluorometholone ophthalmic suspension. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results